US biotech major Biogen (Nasdaq: BIIB) opened the large-cap neuroscience earnings run with second-quarter revenue of $2.74 ...
ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading ...
UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty ...
US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug ...
Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) ...
Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from ...
US biotech Outlook Therapeutics revealed that the US Food and Drug Administration (FDA) has approved Lytenava ...
US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...
UK-based Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA ...
Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed ...
Among significant news last week, Halozyme Therapeutics struck a license agreement for its INCA033989 with fellow USA-based ...
US pharma major Johnson & Johnson has reported positive top-line Phase III data showing that a dual bispecific antibody ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results